CN1739625A - 治疗艾滋病的药物 - Google Patents
治疗艾滋病的药物 Download PDFInfo
- Publication number
- CN1739625A CN1739625A CN 200510010999 CN200510010999A CN1739625A CN 1739625 A CN1739625 A CN 1739625A CN 200510010999 CN200510010999 CN 200510010999 CN 200510010999 A CN200510010999 A CN 200510010999A CN 1739625 A CN1739625 A CN 1739625A
- Authority
- CN
- China
- Prior art keywords
- medicine
- aids
- patient
- hiv
- immune deficiency
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 115
- 208000030507 AIDS Diseases 0.000 title claims abstract description 65
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 claims abstract description 22
- 241000628997 Flos Species 0.000 claims description 28
- 229940079593 drug Drugs 0.000 claims description 23
- 239000009636 Huang Qi Substances 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 239000000470 constituent Substances 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 241000545442 Radix Species 0.000 claims description 3
- 238000002481 ethanol extraction Methods 0.000 claims description 3
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000003208 petroleum Substances 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 241001529553 Scoparia <angiosperm> Species 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 3
- 241000725303 Human immunodeficiency virus Species 0.000 abstract description 63
- 150000001875 compounds Chemical class 0.000 abstract description 44
- 230000000694 effects Effects 0.000 abstract description 44
- 241000700605 Viruses Species 0.000 abstract description 21
- 231100000331 toxic Toxicity 0.000 abstract description 9
- 230000002588 toxic effect Effects 0.000 abstract description 9
- 230000036737 immune function Effects 0.000 abstract description 6
- 230000036039 immunity Effects 0.000 abstract description 5
- 230000001976 improved effect Effects 0.000 abstract description 3
- 208000036142 Viral infection Diseases 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- 230000009385 viral infection Effects 0.000 abstract description 2
- 239000000902 placebo Substances 0.000 description 28
- 229940068196 placebo Drugs 0.000 description 28
- 210000004970 cd4 cell Anatomy 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 12
- 239000000796 flavoring agent Substances 0.000 description 11
- 235000019634 flavors Nutrition 0.000 description 11
- 241000411851 herbal medicine Species 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000007812 deficiency Effects 0.000 description 9
- 229960002555 zidovudine Drugs 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 241000721047 Danaus plexippus Species 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000012567 medical material Substances 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 108010082126 Alanine transaminase Proteins 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 230000036436 anti-hiv Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- 208000001388 Opportunistic Infections Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- -1 steroidal Chemical class 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- 229940124321 AIDS medicine Drugs 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010013700 Drug hypersensitivity Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010021036 Hyponatraemia Diseases 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 229930004069 diterpene Natural products 0.000 description 2
- 150000004141 diterpene derivatives Chemical class 0.000 description 2
- 201000005311 drug allergy Diseases 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 210000003677 hemocyte Anatomy 0.000 description 2
- 229940000351 hemocyte Drugs 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical class [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000000088 lip Anatomy 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 206010044008 tonsillitis Diseases 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- LOLNFJHUEIDGNH-PIXDULNESA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-[(e)-2-iodoethenyl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\I)=C1 LOLNFJHUEIDGNH-PIXDULNESA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241001421185 Anomis Species 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 241000202726 Bupleurum Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000005794 Hairy Leukoplakia Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010051131 Mastoptosis Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000011195 Profilin Human genes 0.000 description 1
- 108050001408 Profilin Proteins 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108010021119 Trichosanthin Proteins 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 208000020670 canker sore Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 238000011889 obduction Methods 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 206010030979 oral hairy leukoplakia Diseases 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
<400 | 400-1000 | 1000-10000 | >10000 | |
0周 | 0 | 0 | 0 | 100% |
4周 | 18.75% | 15.60% | 45.30% | 20.30% |
8周 | 17.30% | 13.50% | 44.20% | 25% |
12周 | 27.10% | 12.50% | 41.70% | 18.80% |
mean | median | |||
Cells/ml | % | Cells/ml | % | |
0周 | 376.4 | 18.56 | 348 | 18 |
4周 | 381 | 21.3 | 374 | 21 |
8周 | 375.5 | 21.35 | 360.5 | 20.5 |
12周 | 464.5 | 21.28 | 446 | 21 |
症状 | 病人数目 | 百分数 |
肌痛过敏性鼻炎失眠URI体弱头昏DM胃溃疡结膜炎甲状腺肿气喘扁桃体炎背疼瘘管炎Tenia cruris高血压伤寒月经紊乱乳房下垂头疼拉肚子皮炎口腔溃疡Oral candidiasiisOral Hairy Leukoplakia淋巴结增大皮肤病支气管炎皮肤病膝关节炎手,足皮肤脱落耳鸣皮疹扁桃体炎胃热厌食呕吐瞌睡喉热病态发胖胸痛疲倦/贫血 | 5444322322222111111115221963111111105431111/1 | 17.8614.2914.2914.2910.717.147.1410.717.147.147.147.147.143.573.573.573.573.573.573.573.5717.867.147.143.5732.1421.4310.713.573.573.573.573.573.5735.717.814.310.73.573.573.573.57/3.57 |
有异常试验结果的病人数量 | ||
参数 | 服用药物前 | 服用药物后 |
评价等级HbSGOTSGPTHyponatremia | (1) (2)1 121 14 | (1) (2)1 124 |
备注:HbSGOTSGPTHyponatremia | (1)9.5-10.55-10043.75-87.5130-135 | (2)8.0-9.4 gu/dl>100 U/L87.5-175 U/L123-129 meq/L |
时间 | 司艾特(SH)组 | 安慰剂组 |
0周(N=60) | 4.69±0.44(N=40) | 4.79±0.54(N=20) |
4周(N=60) | 2.93±0.76(N=40) | 3.81±0.77(N=20) |
8周(N=60) | 2.93±0.78(N=40) | 4.18±0.57(N=20) |
12周(N=60) | 2.90±0.63(N=40) | 4.12±0.60(N=20) |
16周(N=59) | 2.80±0.67(N=39) | 4.30±0.64(N=20) |
20周(N=58) | 2.76±0.69(N=39) | 4.18±0.77(N=19) |
24周(N=35)· | 2.65±0.72(N=24) | 4.15±0.89(N=11) |
HIV-RNA下降值 | 司艾特(SH)组 | 安慰剂组 | p-值 |
≥1.0log | 35(89.7%) | 5(26.3%) | <0.001 |
≥1.5log | 29(74.4%) | 2(10.5%) | <0.001 |
≥2.0log | 16(41.0%) | 2(10.5%) | 0.04 |
HIV-RNA下降值 | 司艾特(SH)组 | 安慰剂组 | p-值 |
≥1.0log | 24(100%) | 4(36.4%) | <0.001 |
≥1.5log | 17(70.8%) | 2(18.2%) | 0.01 |
≥2.0log | 13(54.2%) | 1(9.1%) | 0.02 |
时间 | 司艾特(SH)组 | 安慰剂组 |
0周(N=60) | 364±174(N=40) | 430±229(N=20) |
4周(N=60) | 378±182(N=40) | 403±211(N=20) |
8周(N=60) | 365±156(N=40) | 419±246(N=20) |
12周(N=60) | 444±163(N=40) | 483±240(N=20) |
16周(N=59) | 452±213(N=39) | 429±234(N=20) |
20周(N=58) | 463±202(N=39) | 429±234(N=19) |
24周(N=37)· | 424±187(N=24) | 394±189(N=13) |
测定项目 | 司艾特(SH)组(N=40) | 安慰剂组(N=20) | p-值 |
男女比例—男∶女 | 7∶33(男=17.5%) | 4∶16(男=20%) | 1 |
年龄段 | 23-57 | 23-48 | |
平均年龄 | 35.6±8.2 | 31.9±8.1 | 0.1 |
平均体重(Kg) | 52.6±9.5 | 51.4±7.1 | 0.6 |
Heterosexuel | 38/39(97.4%) | 18/19(94.7%) | 1 |
IVDU | 1/39(2.6%) | 1/19(5.2%) | 1 |
KPS=100 | 37(92.5%) | 20(100%) | 1 |
平均病毒载量(log) | 4.69±0.44 | 4.79±0.54 | 0.45 |
平均病毒载量(拷贝) | 81590±97786 | 113513±124352 | 0.43 |
平均值 | 42250 | 89650 | |
范围 | 6500-488000 | 8650-518000 | |
CD4 | 364±174 | 430±229 | 0.21 |
CD4范围 | 103-883 | 64-1025 | |
Hb(gm%) | 12.3±1.9 | 11.9±1.5 | 0.37 |
白细胞 | 6302±1757 | 6910±2476 | 0.29 |
血小板(×103) | 240.2±64.7 | 239.3±64.8 | 0.96 |
FBS | 95±48 | 78±29 | 0.13 |
BUN | 10±3 | 10±2 | 0.99 |
肌酸 | 0.8±0.2 | 0.8±0.2 | 0.49 |
白蛋白 | 4.6±0.4 | 4.5±0.5 | 0.5 |
SGOT | 34±24 | 38±48 | 0.69 |
SGPT | 47±51 | 37±29 | 0.41 |
碱性磷脂酶 | 82±32 | 88±40 | 0.57 |
Na+ | 141±3 | 142±4 | 0.11 |
K+ | 3.9±0.4 | 3.8±0.3 | 0.62 |
Cl- | 104±3 | 105±2 | 0.68 |
HCO3 - | 22.9±3.1 | 22.6±3.1 | 0.68 |
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100109999A CN100443093C (zh) | 2005-08-31 | 2005-08-31 | 治疗艾滋病的药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100109999A CN100443093C (zh) | 2005-08-31 | 2005-08-31 | 治疗艾滋病的药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1739625A true CN1739625A (zh) | 2006-03-01 |
CN100443093C CN100443093C (zh) | 2008-12-17 |
Family
ID=36092250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100109999A Active CN100443093C (zh) | 2005-08-31 | 2005-08-31 | 治疗艾滋病的药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100443093C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107582631A (zh) * | 2017-09-30 | 2018-01-16 | 贾忠 | 一种辅助治疗艾滋病的中药复方及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1569089A (zh) * | 2003-07-12 | 2005-01-26 | 罗飞 | 治疗艾滋病的药物 |
-
2005
- 2005-08-31 CN CNB2005100109999A patent/CN100443093C/zh active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107582631A (zh) * | 2017-09-30 | 2018-01-16 | 贾忠 | 一种辅助治疗艾滋病的中药复方及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100443093C (zh) | 2008-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1251763A (zh) | 中药复方制剂妇科千金片的配制方法 | |
CN101711848B (zh) | 一种辅助治疗肿瘤的中药组合物 | |
CN102698207A (zh) | 一种治疗肝病的中药组合物及其制备方法 | |
CN1709302A (zh) | 治疗慢性盆腔炎的中药制剂及其制备方法 | |
CN107412713A (zh) | 治疗自体免疫性与免疫相关性疾病的中成药、医疗食品及制备方法 | |
CN104225403A (zh) | 一种治疗肺结核的药物组合物及制备方法和用途 | |
CN115837065B (zh) | 一种中药组合物及其用途 | |
CN108186794B (zh) | 一种治疗肺癌的中药组合物及其制备方法和应用 | |
CN105126030A (zh) | 一种辅助抗肺癌的壮药组合物 | |
CN102652819B (zh) | 一种妇炎康分散片及其制备方法 | |
CN103191399A (zh) | 用于治疗支气管哮喘急性发作期的中药组合物 | |
CN100443093C (zh) | 治疗艾滋病的药物 | |
CN103585449A (zh) | 用于治疗偏头痛的中药组合物 | |
CN1712055A (zh) | 一种治疗泌尿系结石的中药制剂(溶石胶囊) | |
CN105727089A (zh) | 含艾叶的药物组合物用于制备治疗肠易激综合症药物中的用途 | |
CN103520684B (zh) | 一种降血糖的中药复合物 | |
CN1435247A (zh) | 治疗泌尿系统结石和尿路感染疾病的中药制剂及其制备方法 | |
CN102274428B (zh) | 一种具有治疗肠易激综合症作用的药物组合物及其制备方法和应用 | |
CN1148217C (zh) | 治疗慢性支气管炎的中成药 | |
CN101474388A (zh) | 一种改进的仙蟾片药物处方及其制备方法 | |
CN104758466A (zh) | 治疗急性胆囊炎的中药制剂及制法 | |
CN1251751C (zh) | 一种治疗慢性肝病及抗肝纤维化的中药及其制备工艺 | |
CN103263581A (zh) | 用于降血糖的双参胶囊 | |
CN103705857B (zh) | 用于预防放射性口腔粘膜反应的中药组合物 | |
CN1186052C (zh) | 一种治疗盆腔炎的药物及其药物制剂和制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: WANG LIHONG Free format text: FORMER OWNER: KUNMING INST. OF BOTANY, CHINESE ACADEMY OF SCIENCES Effective date: 20070216 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20070216 Address after: Baiyun road 650024 Yunnan city of Kunming province (No. 525 Beijing Road, Huayuan 63202) Applicant after: Wang Lihong Address before: 650204 No. 610, Longquan Road, Kunming, Yunnan Applicant before: Kunming Institute of Botany, Chinese Academy of Sciences |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: LIU YONG Free format text: FORMER OWNER: WANG LIHONG Effective date: 20150122 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 650024 TO: 650224 |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150122 Address after: 650224 6-3-202 garden, Beijing Road, Yunnan, Kunming Patentee after: Liu Yong Address before: Baiyun road 650024 Yunnan city of Kunming province (No. 525 Beijing Road, Huayuan 6-3-202) Patentee before: Wang Lihong |